PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a precision oncology company developing small-molecule therapies that target p53 mutations and other p53-related cancers. Its platform is designed to correct the structure of specific mutant p53 proteins and restore their tumor-suppressing function. The lead candidate,… From the company’s description.
In fiscal 2025, PMV Pharmaceuticals, Inc. reported a net loss of $77.74M. Operations used $73.58M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PMV Pharmaceuticals, Inc. does
In the company’s own words
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a precision oncology company developing small-molecule therapies that target p53 mutations and other p53-related cancers. Its platform is designed to correct the structure of specific mutant p53 proteins and restore their tumor-suppressing function. The lead candidate, rezatapopt, is an oral therapy designed to target the p53 Y220C mutation across solid tumor types; it is being studied in the PYNNACLE Phase 1/2 clinical trial. PMV also uses its platform to discover additional candidates aimed at other p53 mutations or related targets. The company’s work focuses on genetically defined cancer patient populations, including patients identified through genomic sequencing, and it plans to commercialize approved products through a focused sales and marketing organization. PMV owns worldwide commercial rights to its programs and relies on third parties to manufacture its candidates. Its pipeline is devoted to research and development, with no reportable business segments described. Its website is https://www.pmvpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PRINCETON, NJ
- Fiscal year end
- December
- CIK
- 1699382
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PMV Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PMV Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PMV Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PMV Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PMV Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”